Literature DB >> 20935522

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.

Masanori Noguchi1, Takashi Mine, Nobukazu Komatsu, Shigetaka Suekane, Fukuko Moriya, Kei Matsuoka, Shigeru Yutani, Shigeki Shichijo, Akira Yamada, Uhi Toh, Kouichiro Kawano, Kouichi Azuma, Hirotsugu Uemura, Kiyotaka Okuno, Kazumasa Matsumoto, Hiroaki Yanagimoto, Ryuya Yamanaka, Masaaki Oka, Satoru Todo, Tetsuro Sasada, Kyogo Itoh.   

Abstract

To investigate immunological biomarkers to predict overall survival of advanced cancer patients under treatment with personalized peptide vaccination, correlations between overall survival and biomarkers, including cytotoxic T lymphocyte (CTL) and immunoglobulin G (IgG) responses to the vaccinated peptides, were investigated in 500 advanced cancer patients who received personalized peptide vaccination from October 2000 to October 2008. The best clinical response was assessed for in 436 patients, 43 patients (10%) had partial response, 144 patients (33%) had stable disease and 249 patients (57%) had progressive, with a median overall survival of 9.9 months. Both lymphocyte counts prior to the vaccination (P = 0.0095) and increased IgG response (P = 0.0116) to the vaccinated peptides, along with performance status (P < 0.0001), well correlated with overall survival. To confirm the superiority of IgG response to CTL response, the samples from advanced castration-resistant prostate cancer patients who survived more than 900 days (n=20) and those who died within 300 days (n=23) were analyzed further. As a result, both the numbers of peptides, to which increased IgG responses were observed, and the fold increases in IgG levels were significantly higher in long-term survivors (P = 0.000282 and P = 0.00045). In contrast, CTL responses were not statistically different between the two groups. Both lymphocyte numbers and IgG response were thus suggested to be biomarkers of cancer vaccine for advanced cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935522     DOI: 10.4161/cbt.10.12.13448

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  18 in total

1.  Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.

Authors:  Tetsuro Sasada; Masanori Noguchi; Akira Yamada; Kyogo Itoh
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 2.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

3.  Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.

Authors:  Munehiro Yoshitomi; Shigeru Yutani; Satoko Matsueda; Tetsuya Ioji; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh; Tetsuro Sasada; Hisafumi Kinoshita
Journal:  Exp Ther Med       Date:  2011-12-20       Impact factor: 2.447

4.  PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.

Authors:  Wenxue Ma; Mingshui Chen; Sharmeela Kaushal; Michele McElroy; Yu Zhang; Cengiz Ozkan; Michael Bouvet; Carol Kruse; Douglas Grotjahn; Thomas Ichim; Boris Minev
Journal:  Int J Nanomedicine       Date:  2012-03-15

5.  Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.

Authors:  Kouichiro Kawano; Naotake Tsuda; Kayoko Waki; Satoko Matsueda; Yoshiro Hata; Kimio Ushijima; Kyogo Itoh; Akira Yamada; Toshiharu Kamura
Journal:  Cancer Sci       Date:  2015-07-22       Impact factor: 6.716

6.  Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.

Authors:  Yoshie Higashihara; Junko Kato; Akihito Nagahara; Kentaro Izumi; Masae Konishi; Tomohiro Kodani; Nobuko Serizawa; Taro Osada; Sumio Watanabe
Journal:  Int J Oncol       Date:  2013-12-31       Impact factor: 5.650

7.  In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.

Authors:  Xu-Dong Tang; Shu-Liang Guo; Guo-Zhen Wang; Ning Li; Yu-Yun Wu; Dian-Chun Fang; Ya-Han Fan; Shi-Ming Yang
Journal:  Cancer Sci       Date:  2013-11-29       Impact factor: 6.716

8.  Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines.

Authors:  Shuko Saku; Uhi Toh; Yuko Takao; Sayaka Sakurai; Akira Yamada; Shigeki Shichijo; Kyogo Itoh; Yoshito Akagi
Journal:  Exp Ther Med       Date:  2021-06-25       Impact factor: 2.447

9.  Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.

Authors:  Shigeru Yutani; Kazuomi Ueshima; Kazumichi Abe; Atsushi Ishiguro; Junichi Eguchi; Satoko Matsueda; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh; Tetsuro Sasada; Masatoshi Kudo; Masanori Noguchi
Journal:  J Immunol Res       Date:  2015-10-11       Impact factor: 4.818

10.  Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.

Authors:  Ryuji Takahashi; Uhi Toh; Nobutaka Iwakuma; Miki Takenaka; Hiroko Otsuka; Mina Furukawa; Teruhiko Fujii; Naoko Seki; Akihiko Kawahara; Masayoshi Kage; Satoko Matsueda; Yoshito Akagi; Akira Yamada; Kyogo Itoh; Tetsuro Sasada
Journal:  Breast Cancer Res       Date:  2014-07-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.